标题
MET/HGF pathway in multiple myeloma: from diagnosis to targeted therapy?
作者
关键词
-
出版物
EXPERT REVIEW OF MOLECULAR DIAGNOSTICS
Volume 15, Issue 7, Pages 881-893
出版商
Informa UK Limited
发表日期
2015-05-13
DOI
10.1586/14737159.2015.1046436
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- HGF/c-Met axis drives cancer aggressiveness in the neo-adjuvant setting of ovarian cancer
- (2015) Marisa Mariani et al. Oncotarget
- Phase I ficlatuzumab monotherapy or with erlotinib for refractory advanced solid tumours and multiple myeloma
- (2014) A Patnaik et al. BRITISH JOURNAL OF CANCER
- MET dysregulation is a hallmark of aggressive disease in multiple myeloma patients
- (2014) Alberto Rocci et al. BRITISH JOURNAL OF HAEMATOLOGY
- Biomarker Analyses from a Placebo-Controlled Phase II Study Evaluating Erlotinib Onartuzumab in Advanced Non-Small Cell Lung Cancer: MET Expression Levels Are Predictive of Patient Benefit
- (2014) H. Koeppen et al. CLINICAL CANCER RESEARCH
- LY2875358, a Neutralizing and Internalizing Anti-MET Bivalent Antibody, Inhibits HGF-Dependent and HGF-Independent MET Activation and Tumor Growth
- (2014) L. Liu et al. CLINICAL CANCER RESEARCH
- A HGF/cMET Autocrine Loop Is Operative in Multiple Myeloma Bone Marrow Endothelial Cells and May Represent a Novel Therapeutic Target
- (2014) A. Ferrucci et al. CLINICAL CANCER RESEARCH
- The potential of miRNAs as biomarkers for multiple myeloma
- (2014) Alberto Rocci et al. EXPERT REVIEW OF MOLECULAR DIAGNOSTICS
- High XBP1 expression is a marker of better outcome in multiple myeloma patients treated with bortezomib
- (2014) M. Gambella et al. HAEMATOLOGICA
- Hepatocyte growth factor pathway upregulation in the bone marrow microenvironment in multiple myeloma is associated with lytic bone disease
- (2013) Ida B. Kristensen et al. BRITISH JOURNAL OF HAEMATOLOGY
- Tivantinib (ARQ197) Displays Cytotoxic Activity That Is Independent of Its Ability to Bind MET--Response
- (2013) P. Michieli et al. CLINICAL CANCER RESEARCH
- Novel Targeting of Phospho-cMET Overcomes Drug Resistance and Induces Antitumor Activity in Multiple Myeloma
- (2013) M. Moschetta et al. CLINICAL CANCER RESEARCH
- Targeting MET: why, where and how?
- (2013) Elena Ghiso et al. CURRENT OPINION IN PHARMACOLOGY
- Anti-c-MET Nanobody®- a new potential drug in multiple myeloma treatment
- (2013) Tobias Schmidt Slørdahl et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- c-MET kinase inhibitors: a patent review (2011 – 2013)
- (2013) Kongkai Zhu et al. EXPERT OPINION ON THERAPEUTIC PATENTS
- Targeting MET kinase with the small-molecule inhibitor amuvatinib induces cytotoxicity in primary myeloma cells and cell lines
- (2013) Cornel Phillip et al. Journal of Hematology & Oncology
- Cross-talk between MET and EGFR in non-small cell lung cancer involves miR-27a and Sprouty2
- (2013) M. Acunzo et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- MET: A Critical Player in Tumorigenesis and Therapeutic Target
- (2013) C. R. Graveel et al. Cold Spring Harbor Perspectives in Biology
- Increased MET and HGF gene copy numbers are associated with trastuzumab failure in HER2-positive metastatic breast cancer
- (2012) G Minuti et al. BRITISH JOURNAL OF CANCER
- Immunohistochemical analysis of hepatocyte growth factor and c-Met in plasma cell disease
- (2012) Karin F Wader et al. HISTOPATHOLOGY
- Bone Marrow Microenvironment in Multiple Myeloma Progression
- (2012) S. Manier et al. JOURNAL OF BIOMEDICINE AND BIOTECHNOLOGY
- Knockdown of c-Met enhances sensitivity to bortezomib in human multiple myeloma U266 cells via inhibiting Akt/mTOR activity
- (2011) WENZHONG QUE et al. APMIS
- Soluble c-Met in serum of patients with multiple myeloma: correlation with clinical parameters
- (2011) Karin F. Wader et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- Genetic Activation of theMETPathway and Prognosis of Patients With High-Risk, Radically Resected Gastric Cancer
- (2011) Francesco Graziano et al. JOURNAL OF CLINICAL ONCOLOGY
- METAmplification Identifies a Small and Aggressive Subgroup of Esophagogastric Adenocarcinoma With Evidence of Responsiveness to Crizotinib
- (2011) Jochen K. Lennerz et al. JOURNAL OF CLINICAL ONCOLOGY
- Cabozantinib (XL184), a Novel MET and VEGFR2 Inhibitor, Simultaneously Suppresses Metastasis, Angiogenesis, and Tumor Growth
- (2011) F. M. Yakes et al. MOLECULAR CANCER THERAPEUTICS
- Multiple Myeloma
- (2011) Antonio Palumbo et al. NEW ENGLAND JOURNAL OF MEDICINE
- c-MET as a potential therapeutic target and biomarker in cancer
- (2011) J. Rafael Sierra et al. Therapeutic Advances in Medical Oncology
- Targeting the HGF/Met signalling pathway in cancer
- (2010) Fabiola Cecchi et al. EUROPEAN JOURNAL OF CANCER
- ARQ 197, a Novel and Selective Inhibitor of the Human c-Met Receptor Tyrosine Kinase with Antitumor Activity
- (2010) N. Munshi et al. MOLECULAR CANCER THERAPEUTICS
- MET signalling: principles and functions in development, organ regeneration and cancer
- (2010) Livio Trusolino et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- c-Met signaling promotes IL-6-induced myeloma cell proliferation
- (2009) Håkon Hov et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- Treatment response to bortezomib in multiple myeloma correlates with plasma hepatocyte growth factor concentration and bone marrow thrombospondin concentration
- (2009) Pour Ludek et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- Expression and mutational analysis ofMETin human solid cancers
- (2008) Patrick C. Ma et al. GENES CHROMOSOMES & CANCER
- Hepatocyte growth factor promotes migration of human myeloma cells
- (2008) R. U. Holt et al. HAEMATOLOGICA
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now